Ronghan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ronghan Liu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Ying Zhang
5 shared publicationsJianning Kang
4 shared publicationsXiaodi Zhang
Central Hospital Affiliated to Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250013, China; Department of Orthopaedic Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China
4 shared publicationsZheng Li
4 shared publications- Bin Ning
Central Hospital Affiliated to Shandong First Medical University Shandong First Medical University & Shandong Academy of Medical Sciences Jinan China
3 shared publications Jiayao Niu
3 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
- 22 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 152, 157870
Ailanthone Hijacks ERK/NF-κB Cascade to Attenuate Osteoclastogenesis for Osteoporosis
- 22 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 152, 157870
Ailanthone Hijacks ERK/NF-κB Cascade to Attenuate Osteoclastogenesis for Osteoporosis
- 6 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 151, 157785
Naringenin alleviates spinal cord injury by ameliorating macrophage/microglia autophagy via progranulin stabilisation
- 6 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 151, 157785
Naringenin alleviates spinal cord injury by ameliorating macrophage/microglia autophagy via progranulin stabilisation
- Open Access
- 21 October 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-16
Fexofenadine protects against osteoarthritis by targeting Smad2 and STAT1 to enhance anabolism and binding cPLA2 to inhibit catabolism
Cartilage metabolism balance chaos is crucial in the development and progression of osteoarthritis (OA), with chronic low-grade inflammation being the primary factor that leads to chondrocyte metabolic dysregulation. Fexofenadine (FFD) is a widely used commercially available anti-allergy compound, which has been shown to reduce inflammation. The present study finds FFD’s therapeutic effects in primary human ex-vivo cultures and surgically induced murine models. Mechanism study illustrates FFD exhibits chondroprotective effect through anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated inflammation and pro-Transforming Growth Factor Beta (TGFβ)-associated anabolism. Specifically, FFD directly binds to cytosolic phospholipase A2 (cPLA2), down-regulating downstream NF-κB activation, resulting in alleviated catabolism. Notably, Signal Transducer and Activator of Transcription 1 (STAT1) is first identified as FFD’s target by Drug affinity responsive target stability which shows the Gln-314 site is required. FFD blocks STAT1 binds to TGF-β type I receptor, leading to secondary SMAD Family Member 2 (Smad2) phorsphorylation, slightly enhances chondrocyte proliferation and matrix production. Importantly, further study demonstrates FFD directly binds Smad2 by the target proteins fishing technique, remarkably active TGFβ-related biological process. These findings provide new insights into the chondroprotective role of FFD with novel target and downstream pathway, offering promising avenues for the treatment of OA.
- 21 October 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-16
Open AccessFexofenadine protects against osteoarthritis by targeting Smad2 and STAT1 to enhance anabolism and binding cPLA2 to inhibit catabolism
Cartilage metabolism balance chaos is crucial in the development and progression of osteoarthritis (OA), with chronic low-grade inflammation being the primary factor that leads to chondrocyte metabolic dysregulation. Fexofenadine (FFD) is a widely used commercially available anti-allergy compound, which has been shown to reduce inflammation. The present study finds FFD’s therapeutic effects in primary human ex-vivo cultures and surgically induced murine models. Mechanism study illustrates FFD exhibits chondroprotective effect through anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated inflammation and pro-Transforming Growth Factor Beta (TGFβ)-associated anabolism. Specifically, FFD directly binds to cytosolic phospholipase A2 (cPLA2), down-regulating downstream NF-κB activation, resulting in alleviated catabolism. Notably, Signal Transducer and Activator of Transcription 1 (STAT1) is first identified as FFD’s target by Drug affinity responsive target stability which shows the Gln-314 site is required. FFD blocks STAT1 binds to TGF-β type I receptor, leading to secondary SMAD Family Member 2 (Smad2) phorsphorylation, slightly enhances chondrocyte proliferation and matrix production. Importantly, further study demonstrates FFD directly binds Smad2 by the target proteins fishing technique, remarkably active TGFβ-related biological process. These findings provide new insights into the chondroprotective role of FFD with novel target and downstream pathway, offering promising avenues for the treatment of OA.
- Open Access
- 5 July 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (13) , e70809
Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi‐Omics Analysis
Osteosarcoma (OS) is an aggressive bone cancer that mainly occurs in children and adolescents. OS patients are mainly treated with neoadjuvant chemotherapy and surgical resection. This treatment is effective for early osteosarcoma. However, the effect declines as the disease progresses. Currently, our research on osteosarcoma is not enough to meet the clinical needs. Exosomes play a critical role in osteosarcoma progression by mediating intercellular communication. They carry molecular signals, including miRNAs and proteins, which can influence tumor growth, metastasis, and drug resistance. Recent studies have shown that exosomes from osteosarcoma cells can promote cell proliferation and migration, making them potential biomarkers for early diagnosis and therapeutic targets in osteosarcoma. This opens up new possibilities for the research of osteosarcoma. The combined genes of exosomes and DEGs were identified by searching GeneCards and GEO databases. Subsequent analyses included GO and KEGG Enrichment, GSEA. The core gene set was derived from the intersection of LASSO and SVM‐RFE outputs, ensuring minimal redundancy through dimensionality reduction. Osteosarcoma was diagnosed and predicted by differential expression levels, ROC curve analysis, and nomogram. Immune cell infiltration in osteosarcoma was evaluated by the ssGSEA algorithm. Drug enrichment analysis and molecular docking simulations were conducted to discover the most promising drug leads. In vitro experiments included Wound Healing Assay and qRT‐PCR to detect the therapeutic effect of the drug. Through multiple analyses and dimensionality reduction of the data set, six genes were selected (WNT5A, GCA, ANXA6, BIRC5, IL1β, and ARPC3). We examined differential expression in the control and tumor groups and made a gene prediction nomogram. Analysis of immune cell infiltration revealed significant alterations in the composition of immune cell subsets. Drug enrichment analysis and molecular docking of these six core genes were conducted to screen out the most suitable candidate drug: Mifepristone. Finally, Mifepristone was proved to inhibit the growth of osteosarcoma cells in vitro. Bioinformatics analysis identified six exosome‐associated osteosarcoma genes (WNT5A, GCA, ANXA6, BIRC5, IL1β, and ARPC3) that could serve as potential biomarkers. Through screening, Mifepristone, which can act on BIRC5 and IL1β at the same time, has a very effective osteosarcoma treatment effect.
- 5 July 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (13) , e70809
Open AccessExosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi‐Omics Analysis
Osteosarcoma (OS) is an aggressive bone cancer that mainly occurs in children and adolescents. OS patients are mainly treated with neoadjuvant chemotherapy and surgical resection. This treatment is effective for early osteosarcoma. However, the effect declines as the disease progresses. Currently, our research on osteosarcoma is not enough to meet the clinical needs. Exosomes play a critical role in osteosarcoma progression by mediating intercellular communication. They carry molecular signals, including miRNAs and proteins, which can influence tumor growth, metastasis, and drug resistance. Recent studies have shown that exosomes from osteosarcoma cells can promote cell proliferation and migration, making them potential biomarkers for early diagnosis and therapeutic targets in osteosarcoma. This opens up new possibilities for the research of osteosarcoma. The combined genes of exosomes and DEGs were identified by searching GeneCards and GEO databases. Subsequent analyses included GO and KEGG Enrichment, GSEA. The core gene set was derived from the intersection of LASSO and SVM‐RFE outputs, ensuring minimal redundancy through dimensionality reduction. Osteosarcoma was diagnosed and predicted by differential expression levels, ROC curve analysis, and nomogram. Immune cell infiltration in osteosarcoma was evaluated by the ssGSEA algorithm. Drug enrichment analysis and molecular docking simulations were conducted to discover the most promising drug leads. In vitro experiments included Wound Healing Assay and qRT‐PCR to detect the therapeutic effect of the drug. Through multiple analyses and dimensionality reduction of the data set, six genes were selected (WNT5A, GCA, ANXA6, BIRC5, IL1β, and ARPC3). We examined differential expression in the control and tumor groups and made a gene prediction nomogram. Analysis of immune cell infiltration revealed significant alterations in the composition of immune cell subsets. Drug enrichment analysis and molecular docking of these six core genes were conducted to screen out the most suitable candidate drug: Mifepristone. Finally, Mifepristone was proved to inhibit the growth of osteosarcoma cells in vitro. Bioinformatics analysis identified six exosome‐associated osteosarcoma genes (WNT5A, GCA, ANXA6, BIRC5, IL1β, and ARPC3) that could serve as potential biomarkers. Through screening, Mifepristone, which can act on BIRC5 and IL1β at the same time, has a very effective osteosarcoma treatment effect.
- Open Access
- 19 April 2025
- Published by Wiley in Cell Proliferation
- Vol. 58 (6) , e70031
IMPDH2's Central Role in Cellular Growth and Diseases: A Potential Therapeutic Target
IMPDH2 is a rate-limiting enzyme in guanine nucleotide biosynthesis. It plays diverse roles in various physiological and pathological processes: nucleotide metabolism, inflammation, immune function, ribosomal stress. Structural or regulatory alterations in IMPDH2 are linked to significant health issues, and critical relevance in disease progression. We aim to underscore the potential of IMPDH2 as a promising therapeutic target for clinical applications.
- 19 April 2025
- Published by Wiley in Cell Proliferation
- Vol. 58 (6) , e70031
Open AccessIMPDH2's Central Role in Cellular Growth and Diseases: A Potential Therapeutic Target
IMPDH2 is a rate-limiting enzyme in guanine nucleotide biosynthesis. It plays diverse roles in various physiological and pathological processes: nucleotide metabolism, inflammation, immune function, ribosomal stress. Structural or regulatory alterations in IMPDH2 are linked to significant health issues, and critical relevance in disease progression. We aim to underscore the potential of IMPDH2 as a promising therapeutic target for clinical applications.
- 24 March 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 211, 115516
Periplocin targets low density lipoprotein receptor-related protein 4 to attenuate osteoclastogenesis and protect against osteoporosis
- 24 March 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 211, 115516
Periplocin targets low density lipoprotein receptor-related protein 4 to attenuate osteoclastogenesis and protect against osteoporosis
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 38 (5) , 775-791
Higenamine Promotes Osteogenesis Via IQGAP1/SMAD4 Signaling Pathway and Prevents Age- and Estrogen-Dependent Bone Loss in Mice
Osteoporosis is a common bone disease caused by an imbalance of bone resorption and formation that results in a loss of total bone density. SMAD2/3 signal transduction is known to play a crucial role in osteogenic differentiation through transforming growth factor-beta (TGF-β). By screening a library of small-molecule compounds, the current study identifies higenamine (HG) as an active osteogenic agent that could be a therapeutic candidate for osteoporosis. In vitro data demonstrated that HG effectively induced expressions of osteogenic markers in mouse bone marrow stromal cell (BMSCs) and preosteoblastic cell cultures. Further, HG treatment resulted in enhanced bone formation and prevented accelerated bone loss on two animal models that mimic spontaneous senile osteoporosis and postmenopausal osteoporosis. IQ motif-containing GTPase-activating protein 1 (IQGAP1) was confirmed as a novel target of HG, where HG appears to bind to the Glu-1019 site of IQGAP1 to exert its osteogenic effects. Data subsequently suggested that HG promoted phosphorylation of SMAD2/3 and regulated the SMAD2/3 pathway by inhibiting SMAD4 ubiquitination. Overall, the findings highlight HG as a new small-molecule drug to promote bone formation through SMAD2/3 pathway in osteoporosis. © 2023 American Society for Bone and Mineral Research (ASBMR). Abstract Higenamine is elucidated to upregulate SMAD2/3 signaling through binding IQGAP1, which leads to the inhibition of SMAD4 ubiquitination and thereby promotion of the expression of key osteogenesis genes.
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 38 (5) , 775-791
Higenamine Promotes Osteogenesis Via IQGAP1/SMAD4 Signaling Pathway and Prevents Age- and Estrogen-Dependent Bone Loss in Mice
Osteoporosis is a common bone disease caused by an imbalance of bone resorption and formation that results in a loss of total bone density. SMAD2/3 signal transduction is known to play a crucial role in osteogenic differentiation through transforming growth factor-beta (TGF-β). By screening a library of small-molecule compounds, the current study identifies higenamine (HG) as an active osteogenic agent that could be a therapeutic candidate for osteoporosis. In vitro data demonstrated that HG effectively induced expressions of osteogenic markers in mouse bone marrow stromal cell (BMSCs) and preosteoblastic cell cultures. Further, HG treatment resulted in enhanced bone formation and prevented accelerated bone loss on two animal models that mimic spontaneous senile osteoporosis and postmenopausal osteoporosis. IQ motif-containing GTPase-activating protein 1 (IQGAP1) was confirmed as a novel target of HG, where HG appears to bind to the Glu-1019 site of IQGAP1 to exert its osteogenic effects. Data subsequently suggested that HG promoted phosphorylation of SMAD2/3 and regulated the SMAD2/3 pathway by inhibiting SMAD4 ubiquitination. Overall, the findings highlight HG as a new small-molecule drug to promote bone formation through SMAD2/3 pathway in osteoporosis. © 2023 American Society for Bone and Mineral Research (ASBMR). Abstract Higenamine is elucidated to upregulate SMAD2/3 signaling through binding IQGAP1, which leads to the inhibition of SMAD4 ubiquitination and thereby promotion of the expression of key osteogenesis genes.